Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05978167 · ClinicalTrials.gov registry record · Early Phase 1
Targeting Drug Memories With Methylphenidate
A Early Phase 1 study of Cocaine Use Disorder and Substance Use Disorder, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- Early Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT05978167 is a Early Phase 1 study of Cocaine Use Disorder and Substance Use Disorder that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 51 participants, below the 102-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05978167, a Early Phase 1 study of Cocaine Use Disorder and Substance Use Disorder, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo will be administered to individuals with cocaine use disorders (CUD) to peak during the retrieval of a drug-cue memory before extinction; in addition to fMRI activations, skin conductance responses (SCR, acquired simultaneously) will serve as the psychophysiological indicators of memory modification. Assessments of interference with the return of drug-cue memories via SCR and craving will be conducted the day following MRI. This pharmocologically-enhanced behavioral approach to decreasing drug memories and craving in iCUD could ultimately be used to develop effective cue-exposure therapies for drug addiction. Procedures include MRI, blood draw, questionnaires and interviews, skin conductance response measures, and behavioral tasks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methylphenidate
- BEHAVIORAL Memory reconsolidation
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-07-05 |
| Est. Completion | 2026-09-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05978167
The ClinicalTrials.gov registry entry for NCT05978167 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (50% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cocaine Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05978167 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05978167 about?
NCT05978167 is a clinical study titled "Targeting Drug Memories With Methylphenidate". This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo wi...
What is the current status of trial NCT05978167?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 51 participants. The study started on 2023-07-05. Estimated completion is 2026-09-03.
What conditions does trial NCT05978167 study?
This clinical trial studies the following conditions: Cocaine Use Disorder, Substance Use Disorder.
What interventions are being tested in trial NCT05978167?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG), Memory reconsolidation (BEHAVIORAL).
Who is sponsoring clinical trial NCT05978167?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05978167 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cocaine and Pentoxifylline (BED IN 47)
RECRUITING · Early Phase 1
-
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
RECRUITING · Early Phase 1
-
Imaging CRF X NOP Interactions in CUD
RECRUITING · Early Phase 1
-
[C-11]NPA PET-amphetamine in Cocaine Use Disorders
RECRUITING · Early Phase 1
-
Safety Profile of Psilocybin for Cocaine Use Disorder
RECRUITING · Early Phase 1
-
[11C]NOP-1A and Cocaine Use Disorders
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.